Immune checkpoint inhibitors are effective for treating recurrent or metastatic HNSCC,10,11 and have been actively investigated in the concurrent and adjuvant setting in previously untreated populations undergoing radiotherapy,12,13 including cisplatin-ineligible populations.14,15 Durvalumab, a PD-L1 inhibitor, showed initial promise in patients with HNSCC,16 with low toxicity, and was thus an attractive strategy to augment outcomes for medically frail patients unfit for cisplatin. Here, CD274 is linked to head and neck squamous cell carcinoma.